A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures
Public ClinicalTrials.gov record NCT00387686. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3, Multicenter, Double-Blind, Randomized, Controlled Study Of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) In Closed Diaphyseal Tibial Fracture
Study identification
- NCT ID
- NCT00387686
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Enrollment
- 367 participants
Conditions and interventions
Conditions
Interventions
- rhBMP-2/CPM Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2006
- Primary completion
- Jun 30, 2009
- Completion
- Feb 28, 2010
- Last update posted
- Feb 27, 2013
2006 – 2010
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | 35294-3708 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35294 | — |
| Pfizer Investigational Site | Aurora | Colorado | 80012 | — |
| Pfizer Investigational Site | Denver | Colorado | 80204 | — |
| Pfizer Investigational Site | New Haven | Connecticut | 06519 | — |
| Pfizer Investigational Site | Pinellas Park | Florida | 33781 | — |
| Pfizer Investigational Site | Fort Wayne | Indiana | 46804 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | 46202 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21201-1595 | — |
| Pfizer Investigational Site | Kalamazoo | Michigan | 49007 | — |
| Pfizer Investigational Site | Portage | Michigan | 49002 | — |
| Pfizer Investigational Site | Lebanon | New Hampshire | 03756 | — |
| Pfizer Investigational Site | New Brunswick | New Jersey | 08901 | — |
| Pfizer Investigational Site | Brooklyn | New York | 11220 | — |
| Pfizer Investigational Site | Elmhurst | New York | 11373 | — |
| Pfizer Investigational Site | Charlotte | North Carolina | 28203-5871 | — |
| Pfizer Investigational Site | Memphis | Tennessee | 38103 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00387686, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 27, 2013 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00387686 live on ClinicalTrials.gov.